Notes 1 For 25-03 Good Laboratory Practices PDF
Notes 1 For 25-03 Good Laboratory Practices PDF
Notes 1 For 25-03 Good Laboratory Practices PDF
PRACTICES
D r. G a u r a v Ti w a r i
GLP: GOOD LABORATORY PRACTICE
• GLP is an FDA regulation.
• GLP is a formal regulation that was created by the FDA
(United states food and drug administration) in 1978.
Definition of GLP
•In the early 70’s FDA became aware of cases of poor laboratory
practice all over the United States.
Test systems
Archiving of records and materials
Apparatus, material and reagent facilities
Quality assurance programs
Performance of the study
Reporting of study results
Standard operating procedures (SOPs)
Personnel and test facility organization
THE PRINCIPLES OF GLP IN
GENERAL
1) Protocol
4.Names and address of the sponsor, test facility and test site
5.Name of the study director and other personnel
6.Proposed dates
2)
Information of the specimens should be present on the
container to avoid error in recording and storage of data.
3)
All the data generated shall be recorded directly, promptly and
legibly by ink.
12. D ISQUALIFICATION OF TESTING FACILITY
Before a workplace can experience the
consequences of noncompliance, an
explanation of disqualification isneeded
07/15/13
POSSIBLE VIOLATIONS
07/15/13 25
UPON D ISQUALIFICATION …
If the commissioner finds that the facility was noncompliant on any of the grounds
after the hearing, then a final order of noncompliance will be sent to the facility with
explanations.
If a testing facility has been disqualified, any studies done before of after the
disqualification will need to be determined asessential to a decision (acceptable ornot)
If the study is determined unacceptable, then the facility itself may need to show that
the study was not affected by the noncompliance that led to the disqualification
Once finally disqualified, the facility may not receive or be considered for a research or
marketing permit and the study is rejected.
The commissioner may notify the public and all interested persons, including other
federal agencies the facility may havecontacted.
The FDA may ask the other agencies to consider whether to support the facility or not
under the disqualification
TheFDA may turn itover to the federal, state or local law enforcement
The facility’s sponsor may terminate or suspend the facility from doing any non- clinical
study forapermit.
The sponsor is required to notify the FDA In writing within 15 working days that the
facility is to be suspendedor terminated andwhy